ViaCyte added its first chief financial officer to its C-suite, bringing on Brittany Bradrick from Massachusetts-based medical device company Insulet (NASDAQ: [[ticker:PODD]]) where she served as vice president of strategy and corporate development.
Bradrick’s prior experience includes roles in the diabetes care division at Abbott (NYSE: [[ticker:ABT]]). Before entering the industry she spent about a decade working with life sciences companies as an investment banker with Chase Securities, Credit Suisse, and Piper Jaffray (NYSE: [[ticker:PIPR]]).
San Diego-based ViaCyte earlier this year added a private investment round of $27 million to continue advancing its investigational cell therapy programs, which use stem cells that are differentiated into pancreatic islet cells that can create insulin to treat people with diabetes. The cells are embedded in devices, which are implanted under the skin of patients. The company has a collaboration with W. L. Gore, the maker of Gore-Tex, to create the devices for one of its programs.
